Owlstone Medical
Top Five Articles on 360Dx Last Week: LabCorp Ordered to Pay Ravgen Another $100M; More
Last week, readers were most interested in a story on Labcorp being ordered to pay an additional $100 million to Ravgen in a patent lawsuit.
SQI Diagnostics, Owlstone Medical Ink MOU for Lung Infection, Transplant Rejection
The companies intend to work together on breath-based biomarkers for Aspergillus lung infection and lung transplant rejection.
Owlstone Medical Raises $58M in Series D Financing Round
The company said it has a pipeline of research-use-only panels and diagnostic tests that are in development for lung cancer, liver disease, and respiratory disease.
Long-Haul COVID-19 Respiratory Infections, Pneumonia Targeted by Breath-Based Tests From Avisa Dx
Premium
Avisa is preparing an Investigational Device Exemption application to the FDA to facilitate a pivotal study for its portable, point-of-care drug-device breath tests.
Owlstone Medical Entering Digestive Health Dx Space With Launch of Breath-Based Testing Service
Premium
The company is preparing to provide a clinical testing service that integrates hydrogen and methane biomarkers for digestive health conditions.
Sep 19, 2019
Mar 21, 2019
Feb 20, 2019
Nov 7, 2018